Study Stopped
Difficulties of recruitment, lack of elligible patients
In Vivo Hip Fracture Discrimination With Quantitative Computed Tomography (QCT)
FEMFRACT
In Vivo Discrimination of Hip Fracture With Quantitative Computed Tomography
1 other identifier
observational
107
1 country
1
Brief Summary
Numerous geometric and bone mineral density (BMD) parameters can be derived from quantitative computed tomography (QCT) images of the proximal femur analyzed using dedicated software. The primary objective is to evaluate the contribution of QCT-image analysis to the prediction of the osteoporotic hip fracture risk, as compared to the reference standard, namely, dual energy X-ray absorptiometry (DXA). Study hypothesis: For predicting osteoporotic hip fracture, findings from QCT images of the proximal femur analyzed using dedicated software are superior over DXA measurements of proximal femoral BMD.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Feb 2005
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2008
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2009
CompletedFirst Submitted
Initial submission to the registry
December 17, 2009
CompletedFirst Posted
Study publicly available on registry
December 18, 2009
CompletedDecember 18, 2009
March 1, 2008
3.1 years
December 17, 2009
December 17, 2009
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The primary objective is to evaluate the contribution of QCT-image analysis to the prediction of the osteoporotic PFF risk, as compared to the reference standard, namely, DXA.
1 month
Secondary Outcomes (3)
To compare the value of BMD parameters and geometric parameters in predicting osteoporotic PFFs
1 month
To compare the roles for cortical bone and trabecular bone in predicting osteoporotic PFFs
1 month
To look for differences between cervical and trochanteric hip fractures
1 month
Study Arms (2)
Control
Women without hip fracture, matched on age to the cases
Patient
Female patients aged 60 and older with hip fracture
Eligibility Criteria
Women with a history of osteoporotic hip fracture (cases) will be recruited while hospitalized in one of the study centres for immediate care of their fracture. Women without osteoporotic fractures (controls) matched on age to the cases will be recruited while receiving outpatient or inpatient care at one of the study centres. Inclusion and exclusion criteria are detailed below
You may qualify if:
- Selection of cases: women with hip fracture
- woman aged 60 years and more
- clinical suspicion of osteoporosis based on the following: trivial trauma (fall from the standing position), history of vertebral fracture or visualization of a vertebral fracture by CT
- availability of radiographs of the proximal femur (anteroposterior view of the pelvis mandatory; anteroposterior and lateral views of the fractured hip optional)
- signature by the patient of the informed consent document
You may not qualify if:
- patient under 60 years
- current bisphosphonate, oestrogen, or SERM treatment started more than 3 months earlier; or past treatment with these medications stopped less than 6 months earlier
- hip arthroplasty on the other side
- fracture at the site of a bone lesion
- psychiatric disorder that might prevent the patient from giving informed consent or from remaining completely still for about 15 minutes during the investigations
- informed consent document not signed by the patient
- Selection of controls:
- The controls will be women without hip fracture matched on age to the cases.
- woman aged 60 years and more
- signature by the patient of the informed consent document
- age under 60 years
- male
- current bisphosphonate, oestrogen, or SERM therapy started more than 3 months earlier; or past treatment with these medications stopped less than 6 months earlier
- history of osteoporotic hip fracture.
- psychiatric disorder that might prevent the patient from giving informed consent or from remaining completely still for about 15 minutes during the investigations
- +1 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hôpital Lariboisière - APHP
Paris, 75010, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Valérie BOUSSON, PH
Assistance Publique - Hôpitaux de Paris
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
December 17, 2009
First Posted
December 18, 2009
Study Start
February 1, 2005
Primary Completion
March 1, 2008
Study Completion
March 1, 2009
Last Updated
December 18, 2009
Record last verified: 2008-03